Product Images Aprepitant

This is a warning label for a medication called "Capsules, USP," with a strength of 125mg. It contains six capsules in a unit-dose package that is not child-resistant and intended for institutional use only. There is a warning not to use the medication if the blisters are torn, broken or missing.*

This is a unit-dose package of Aprepitant Capsule, USP with NDC number 0781232105. The package warns that it is not child-resistant and should not be used if torn, broken or missing.*

Aprepitant Capsules, USP are a prescription medication used to prevent nausea and vomiting caused by chemotherapy or surgery. The usual dosage is not specified and can be found in the package insert. The capsules should be stored at room temperature and protected from moisture, and kept out of the reach of children. The package contains 5 capsules of 40mg each and should not be used if the capsules are damaged, broken, or missing. The unit-dose package is not child-resistant and should be used for institutional use only. The manufacturer is Lok Phamscauticals dd. in Slovenia, and the product is distributed by Sandoz Inc. in Princeton, NJ. The product is from India and has a lot and expiration number.*

This seems to be a set of instructions and information for a medication called "Apfepitant Capsules, USP" used to prevent nausea and vomiting before chemotherapy. It includes details on dosing, usage for adults and pediatric patients, and how to remove capsules. The beginning of the text appears to be errors and not coherent information.*

Aprepitant Capsules, USP with NDC 0781-2322-68 is a prescription medication that should not be used if the blisters are torn, broken, or missing. The package is not child-resistant and should be stored at 20°- 25°C. Each capsule contains 80 mg of Aprepart, and the usual dosage should be determined by referring to the package insert. This product is for institutional use only and should be kept out of the reach of children.*

This appears to be a table with results from two studies (Study 1 and Study 2) comparing the effectiveness of an "Aprepitant Regimen" versus "Standard Therapy" for a group of patients. The table shows the percentage of patients who responded to each treatment at various time intervals (0, 24, 48, 72, 96 and 120 hours). There is a p-value included indicating that there was a statistically significant difference between the two treatments.*

This appears to be a table comparing the use of Aprepitant Regimen versus Standard Therapy in two separate studies (Study 1 and Study 2). The table shows the number of patients (N) who received either Aprepitant or Standard Therapy at different points in their chemotherapy cycle. The number of patients seems to increase from cycle 2 to cycle 6 in both studies. However, it is unclear what type of cancer or chemotherapy treatment is being studied.*